MREO — Mereo BioPharma Share Price
Last trade - 00:00- $45.17m
- $15.05m
- $0.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 3.83% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.58 | ||
| Price to Tang. Book | 1.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -117.78% | ||
| Return on Equity | -67.85% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 50.14 | n/a | 10 | n/a | 0.5 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Directors
- Denise Scots-Knight CEO (66)
- Anders Ekblom NID (71)
- Charles Sermon GCN (55)
- Michael Wyzga NEC (71)
- Deepika Pakianathan NID (60)
- Alexandra Hughes-Wilson OTH (53)
- Jeremy Bender NID (54)
- Christine Fox CFO (44)
- John Lewicki CSO (73)
- Pierre Jacquet NID (58)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- March 10th, 2015
- Public Since
- June 9th, 2016
- No. of Employees
- 39
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 798,093,044
- Address
- One Cavendish Place, Fourth Floor, NaN, LONDON, W1G0QF
- Web
- https://www.mereobiopharma.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Latest News for MREO
Upcoming Events for MREO
Q3 2026 Mereo BioPharma Group PLC Earnings Release
Q4 2026 Mereo BioPharma Group PLC Earnings Release
Similar to MREO
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 21:03 UTC, shares in Mereo BioPharma are trading at $0.28. This share price information is delayed by 15 minutes.
Shares in Mereo BioPharma last closed at $0.28 and the price had moved by -83.92% over the past 365 days. In terms of relative price strength the Mereo BioPharma share price has underperformed the S&P500 Index by -85.33% over the past year.
The overall consensus recommendation for Mereo BioPharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMereo BioPharma does not currently pay a dividend.
Mereo BioPharma does not currently pay a dividend.
Mereo BioPharma does not currently pay a dividend.
To buy shares in Mereo BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.28, shares in Mereo BioPharma had a market capitalisation of $45.17m.
Here are the trading details for Mereo BioPharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MREO
Based on an overall assessment of its quality, value and momentum Mereo BioPharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mereo BioPharma is $174.67. That is 61620.26% above the last closing price of $0.28.
Analysts covering Mereo BioPharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.03 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mereo BioPharma. Over the past six months, its share price has outperformed the S&P500 Index by +13.93%.
As of the last closing price of $0.28, shares in Mereo BioPharma were trading -13.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mereo BioPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mereo BioPharma's management team is headed by:
- Denise Scots-Knight - CEO
- Anders Ekblom - NID
- Charles Sermon - GCN
- Michael Wyzga - NEC
- Deepika Pakianathan - NID
- Alexandra Hughes-Wilson - OTH
- Jeremy Bender - NID
- Christine Fox - CFO
- John Lewicki - CSO
- Pierre Jacquet - NID